Teva buys rights for Israeli co Biologic’s asthma treatment
Categories: Hi-Tech
Teva Pharmaceutical Industries has completed an exclusive license agreement with Israeli company, Biolojic Design, which is developing a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma..
Agmon with Tulchinsky represented Teva, with the agreement led by partner, Lana Tavor. Teva will oversee the completion of Biologic’s antibody-based therapy for asthma and skin asthma treatment, gaining exclusive licensing rights to market the drug.
Sidley represented Biolojic Design Ltd., a biotechnology company that uses computational biology and artificial intelligence to transform antibodies into intelligent medicinal solutions. The team was led Asher Rubin (Technology and Life Sciences Transactions), and Eden Moalem (Emerging Companies and Venture Capital), and included Yahel Kaplan (Emerging Companies and Venture Capital), and Cassidy A. Pomeroy-Carter (Technology and Life Sciences Transactions).
